Evidence map›Paper›PMID 40176606›Full record

ArticleThe Australasian journal of dermatology2025

Exploring the Impact of Guselkumab and Risankizumab on Psoriasis in HIV-Positive Patients: Insights From Four Italian Centers.

V Maione, S Rovaris, C Romanó, S Bighetti, M Arisi, C G Carrera, F Bellinato, P Gisondi, Z Fratton, E Errichetti and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Australasian journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?Journal of inflammation research · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

V MaioneDepartment of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.ORCID https://orcid.org/0000-0002-0420-5009
S RovarisDepartment of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.
C RomanóDepartment of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.
S BighettiDepartment of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.
M ArisiDepartment of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.
C G CarreraDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
F BellinatoDepartment of Medicine, Section of Dermatology, University of Verona, Verona, Italy.
P GisondiDepartment of Medicine, Section of Dermatology, University of Verona, Verona, Italy.
Z FrattonInstitute of Dermatology, Department of Medicine, University of Udine, Udine, Italy.
E ErrichettiInstitute of Dermatology, Department of Medicine, University of Udine, Udine, Italy.
L BettoliniDepartment of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV-positive patients with psoriasis often face delays in accessing biologic therapies due to their exclusion from clinical trials and concerns about the impact of immunomodulatory drugs on viral replication. Anti-IL-23 therapies, such as risankizumab and guselkumab, have shown great promise thanks to their strong efficacy and favourable safety profiles. A case series from four Italian centres reported sustained effectiveness of these drugs, with no observed effects on viral replication or immune parameters in HIV-positive patients. Although the number of cases is limited, these therapies appear to be a compelling option for patients with extensive or treatment-resistant psoriasis.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedDermatologic AgentsHIV InfectionsPsoriasisAdultFemaleHumansItalyMaleMiddle AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDermatologic AgentsguselkumabrisankizumabbiologicsHIVpsoriasis

Identifiers

PMID40176606
PMCPMC12145727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.